FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus

Basel, 06 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses and newborn infants cobas Zika complements efforts to prevent the spread of Zika virus through blood donations in the U.S. cobas Zika... Read more

Mining and Soil Modes Added to Smallest and Lightest Handheld XRF Elemental Analyzer

Mining and Soil Modes Added to Smallest and Lightest Handheld XRF Elemental Analyzer Thermo Scientific Niton XL5 handheld XRF analyzer now offers additional functionality and new accessories, including collapsible mini test stand TEWKSBURY, Mass., Oct. 2, 2017 /PRNewswire/ — Geologists, mining companies and environmental laboratories can now generate x-ray fluorescence (XRF) analysis faster in the... Read more

FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer

Basel, 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin®... Read more

FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer

Basel, 29 September 2017 FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Perjeta® (pertuzumab), in combination with Herceptin®... Read more

Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx SANTA CLARA, Calif., September 22, 2017 Agilent Technologies Inc. (NYSE: A) today announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by U.S. Food and Drug... Read more

State Key Laboratory of Biochemical Engineering and PerkinElmer Open Joint Translational Medical Engineering Demonstration Laboratory in Beijing

New Facility Helps Scientists Advance Translational Medical Research WHAT:              PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the opening of the Translational Medical Engineering Demonstration Laboratory at a ceremony on September 19.  Co-founded with the State Key Laboratory of Biochemical Engineering, this facility will serve as a center for... Read more

Thermo Fisher Scientific Laboratory Freezers Earn U.S. EPA ENERGY STAR Rating

Thermo Fisher Scientific Laboratory Freezers Earn U.S. EPA ENERGY STAR Rating WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ — Laboratories can now rely on Thermo Fisher Scientific’s expanded line of cold-storage products to help them meet their goals for both productivity and sustainability. The company recently earned the U.S. Environmental Protection Agency’s (EPA’s) ENERGY STAR certification... Read more

Agilent Obtains U.S. FDA Approval for GenetiSure Dx Postnatal Assay

Assay Detects Genetic Anomalies and Helps Move Inquiries from Cause to Care Faster SANTA CLARA, Calif., September 13, 2017 Agilent Technologies Inc. (NYSE: A) has announced that it has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the GenetiSure Dx Postnatal Assay: its first comparative genomic hybridization (CGH) assay for diagnostic... Read more

Illumina Files New Patent Infringement Suit Against Premaitha Health plc

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) announced today that the company has filed a new patent infringement suit against Premaitha Health plc in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom. Illumina is seeking all available remedies, including damages and injunctive relief. The new suit accuses Premaitha’s IONA® Test of infringing... Read more